ERBB2 and neoplasm: Of 301 enrolled pts, 154 were randomized to the VG and 147 to the CG. There were no differences in age, grade, receptor status, tumor size or nodal status between groups (all P ≥ .1). Five-year DFS rates were not different with 82% (VG) vs 79.9% (CG), HR = 0.96, P = .9. There were trends in several subgroups. In HER2 1–2 + pts (77 VG vs 80 CG), 5 yr DFS was 79% (VG) vs 75% (CG), HR 0.76, P = .48. In ER/PR− pts (59 VG vs 56 CG), 5 yr DFS was 83% (VG) vs 77% (CG), HR 0.67, P = .36. In TNBC pts (25 VG vs 26 CG), 5 yr DFS was 67% (VG) vs 62% (CG), HR 0.65, P = .42.